当前位置: X-MOL首页全球导师 国内导师 › 顾淑燕

个人简介

助理研究员 所在院系:政府管理学院劳动人事与社会保障系 学术交流 · 2017.08-2018.09 美国杜兰大学 公共卫生与热带医学学院 访问学者 · 2016.07-2016.10 中国医学科学院肿瘤医院 国家癌症中心 参与城市癌症早诊早治卫生经济学评估项目 主要学术会议 · 2018年参加国际会议“International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting”,作为第一作者发表1篇会议海报. · 2017年参加国际会议“The International Doctoral Student Conference”,作为第一作者进行口头汇报. · 2016年参加国际会议“International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 7th Asia-Pacific Conference”,作为第一作者发表2篇会议海报. · 2016年参加国际会议“2016 Chinese Economists Society Annual Conference”,作为第一作者进行口头汇报. · 2016年参加国际会议“Health Technology Assessment International (HTAi) 2016 Annual Meeting”,作为第一作者进行2次口头汇报. · 2015年参加国内会议“中华预防医学会社会医学分会第十一次全国社会医学学术年会”,作为第一作者发表1篇会议论文. · 2015年参加国际会议“Symposium on Social Determinants of Health”,作为嘉宾在会上发言并参与讨论. · 2015年参加国际会议“12th Health Technology Assessment International (HTAi) Annual Meeting”,作为第一作者发表1篇会议海报. · 2014年参加国际会议“International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 6th Asia-Pacific Conference”,作为第一作者发表1篇会议海报. · 2013年参加国内会议“中华预防医学会第四届学术年会”,作为第一作者发表1篇会议论文.

研究领域

卫生经济学、卫生技术评估、健康行为与生命质量评估、健康管理

近期论文

查看导师新发文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

· Shuyan Gu, Xiaoyong Wang, Qing Qiao, Weiguo Gao, Jian Wang, Hengjin Dong. Cost-Effectiveness of Exenatide Twice Daily vs Insulin Glargine as Add-on Therapy to Oral Antidiabetic Agents in Patients with Type 2 Diabetes in China. Diabetes Obes Metab. 2017;19(12):1688-97. · Shuyan Gu, Yiming Mu, Suodi Zhai, Yuhang Zeng, Xuemei Zhen, Hengjin Dong. Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China. PLoS One. 2016;11(11):e0165629. · Shuyan Gu, Huimei Hu, Hengjin Dong. Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension. PharmacoEconomics. 2016;34(6):533-50. · Shuyan Gu, Yuhang Zeng, Demin Yu, Xiaoqian Hu, Hengjin Dong. Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China. PLoS One. 2016;11(11):e0167190. · Shuyan Gu, Huimei Hu, Hengjin Dong. Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension. PharmacoEconomics. 2016;34(8):751-70. · Shuyan Gu, Jing Deng, Lizheng Shi, Yiming Mu, Hengjin Dong. Cost-Effectiveness of Saxagliptin vs Glimepiride as a Second-Line Therapy Added to Metformin in Type 2 Diabetes in China. J Med Econ. 2015;18(10):808-20. · Shuyan Gu, Jihao Shi, Zhiliu Tang, Monika Sawhney, Huimei Hu, Lizheng Shi, Vivian Fonseca, Hengjin Dong. Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: a Meta-Analysis. PLoS One. 2015;10(5):e0126704. · Shuyan Gu, Zhiliu Tang, Lizheng Shi, Monika Sawhney, Huimei Hu, Hengjin Dong. Cost-Minimization Analysis of Metformin and Acarbose in Treatment of Type 2 Diabetes. Value Health Reg Issues. 2015;6:84-8. 摘要收录期刊论文 · Gu S, Wang X, Shi L, Hu X, Gu Y, Huang M, Dong H. VALUING HEALTH-RELATED QUALITY OF LIFE FOR INPATIENTS WITH DIABETES-RELATED COMPLICATIONS IN CHINA. Value in Health, 2018, 21(S1): S77-8. · Gu S, Hu H, Dong H. SYSTEMATIC REVIEW OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Value in Health, 2016,19(3): A118. · Gu S, Dong H. COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS ACARBOSE AS A MONOTHERAPY IN TYPE 2 DIABETES IN CHINA. Value in Health, 2016, 19(7): A898. · Gu S, Shao H, Zeng Y, Shi L, Dong H. COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS ACARBOSE AS SECOND-LINE THERAPY IN TYPE 2 DIABETES IN CHINA. Value in Health, 2016, 19(7): A898. · Gu S, Xu X, Shi L, Sawhney M, Hu H, Dong H. COST MINIMIZATION ANALYSIS OF CLINICAL OPTION SCENARIOS FOR METFORMIN AND ACARBOSE IN TREATMENT OF TYPE 2 DIABETES: BASED ON DIRECT AND INDIRECT TREATMENT COMPARISON RESULTS. Value in Health, 2014, 17(7): A745. 会议论文 · 顾淑燕,董恒进,杨芊,张皓,郜琳,甄雪梅,曾玉航,胡晓茜. 大气细颗粒物污染对居民造成的疾病负担的研究. 中华预防医学会社会医学分会第十一次全国社会医学学术年会, 2015. · 顾淑燕,董恒进,杨芊,刘小方,张皓,胡慧美,王林浩,郜琳. 二甲双胍与阿卡波糖治疗2型糖尿病的文献研究. 中华预防医学会第四届学术年会, 2013.

推荐链接
down
wechat
bug